EHA 2026 | Future directions in ALL: targeted therapies and chemotherapy-free approaches
Anthony Moorman, PhD, Newcastle University, Newcastle, UK, discusses future directions in acute lymphoblastic leukemia (ALL) treatment and research, highlighting the growing impact of blinatumomab and the move toward increasingly targeted and potentially chemotherapy-free approaches in B-cell ALL. Prof. Moorman also addresses ongoing challenges in T-ALL, including the need for improved frontline risk stratification using measurable residual disease (MRD), methylation profiling, and genomic risk models to help prevent relapse and improve long-term outcomes. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
